AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial

Baxdrostat, an investigational aldosterone synthase inhibitor from AstraZeneca, significantly lowered blood pressure in patients with uncontrolled or resistant hypertension, according to data presented at ESC Congress 2025 and simultaneously published in a leading journal1 3 5 6.

The phase III BaxHTN and Bax24 trials showed baxdrostat, given once daily at 1 mg or 2 mg doses, produced reductions in seated systolic blood pressure of 8.7 mm Hg and 9.8 mm Hg, respectively, compared to placebo at 12 weeks; effects were sustained for at least 32 weeks1 3 5 6.

Ambulatory 24-hour average systolic blood pressure dropped significantly, achieving the trial's primary endpoint and confirming efficacy throughout the 24-hour period, including early morning when cardiovascular event risk is higher2 4 7.

Baxdrostat demonstrated a statistically significant and highly clinically meaningful 14.0 mmHg placebo-adjusted reduction in 24-hour systolic blood pressure in the Bax24 trial, further supporting its value for patients with resistant hypertension7.

Nearly 40% of patients receiving baxdrostat achieved target systolic BP below 130 mm Hg, compared with 18.7% on placebo, highlighting its strong potential for hard-to-control hypertension3.

Safety data show baxdrostat is generally well tolerated, with mild adverse events and a low incidence of hyperkalemia; no reports of adrenocortical insufficiency were noted1 5 6.

Baxdrostat's long half-life (26-30 hours) enables once-daily dosing and could offer competitive advantages compared to similar drugs such as lorundrostat, providing consistent blood pressure control over 24 hours2.